Eton Pharmaceuticals
Eton Pharmaceuticals is a commercial-stage rare disease pharmaceutical company that acquires, develops, and commercializes proprietary formulations of approved molecules for ultra-rare pediatric endocrine, metabolic, and specialty conditions, distributing ten products primarily through specialty pharmacy partners in the US.
- Company typePublic
- Founded2017
- HeadquartersStudio City, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Eton Pharmaceuticals does
Eton Pharmaceuticals is a commercial-stage rare disease pharmaceutical company founded in 2017 and listed on NASDAQ (ETON), headquartered in Deer Park, Illinois. The company acquires, develops, and commercializes treatments for rare diseases — predominantly ultra-rare pediatric endocrine and metabolic disorders — by sourcing approved or near-approved molecules globally (US and Europe), pursuing FDA approval through known regulatory pathways, and commercializing through specialty pharmacy networks. Its core technology centers on proprietary formulations of approved molecules designed to be safer, more effective, or more convenient than existing products, including the first and only FDA-approved oral liquid desmopressin (DESMODA, patent protection through 2044) and pediatric-appropriate hydrocortisone formulations (ALKINDI SPRINKLE, KHINDIVI).
The company's commercial portfolio comprises approximately ten products spanning pediatric endocrinology (Increlex for severe IGF-1 deficiency, ALKINDI SPRINKLE, KHINDIVI), inherited metabolic disorders (Carglumic Acid, Betaine Anhydrous, Nitisinone, PKU GoLike, TYR GoLike), Wilson disease (GALZIN), infantile hemangioma (HEMANGEOL), central diabetes insipidus (DESMODA), and leishmaniasis (IMPAVIDO, rights effective September 2026). Two pipeline candidates — ET-700 (extended-release zinc acetate for Wilson disease, in clinical study) and ET-801 (ready-to-use hydrocortisone for adrenal insufficiency crises, partnered with CROSSJECT) — represent the next growth layer. Products are distributed primarily through Anovo Specialty Pharmacy under an exclusive relationship, supported by the Eton Cares patient support program offering $0 co-pay for eligible commercially insured patients.
Eton's business model is asset-light and deal-driven: revenue is generated through product sales and licensing royalties, with growth funded by a cadence of in-licensing and acquisition transactions (Increlex from Ipsen in late 2024, HEMANGEOL from Pierre Fabre effective May 2026, IMPAVIDO from Knight Therapeutics effective September 2026). The model emphasizes rapid commercialization of products with existing safety/efficacy data and demonstrated demand (including off-label or compounding patterns), reducing development risk and time-to-market. Q1 2026 product sales reached $24.3M (+73% YoY) with management guiding full-year 2026 revenue to >$120M (raised from $110M) and targeting $200M by 2027 and $500M by 2030. The company reported positive net income and adjusted EBITDA in Q1 2026, marking a profitability inflection.
Eton Pharmaceuticals firmographics
Firmographics- Name
- Eton Pharmaceuticals
- Legal name
- Eton Pharmaceuticals, Inc.
- Website
- https://etonpharma.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Eton Pharmaceuticals is a commercial-stage rare disease pharmaceutical company that acquires, develops, and commercializes proprietary formulations of approved molecules for ultra-rare pediatric endocrine, metabolic, and specialty conditions, distributing ten products primarily through specialty pharmacy partners in the US.
- Ownership category
- akta.pro rank
Eton Pharmaceuticals industry classification
Industry- Product category
- Rare Disease Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
- akta.pro secondary industries
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Specialty Care Pharmaceuticals (HLAIAAAB), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Eton Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Studio City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Eton Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations
Revenue model
- Product Sales: Revenue generated from the sale of commercial rare disease products including INCRELEX, ALKINDI SPRINKLE, GALZIN, Carglumic Acid, KHINDIVI, HEMANGEOL, DESMODA, Betaine, Nitisinone, and PKU GoLike. Products are distributed through specialty pharmacy partners.
- Royalty Revenue: Eton receives royalty payments from licensed products in their portfolio.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Eton Pharmaceuticals product offering
Product offeringCore offering
Eton Pharmaceuticals acquires, develops, and commercializes FDA-approved rare disease treatments, including proprietary formulations of approved molecules for pediatric endocrinology, metabolic disorders, and other rare conditions. The company focuses on products with existing safety and efficacy data, targeting rapid commercialization through specialty pharmacy networks. Its commercial portfolio spans ten-plus products including Alkindi Sprinkle, DESMODA, Galzin, Hemangeol, Increlex, Khindivi, Betaine Anhydrous, Carglumic Acid, Nitisinone, PKU GoLike, TYR GoLike, and IMPAVIDO.
Product overview
Eton Pharmaceuticals is a rare disease-focused pharmaceutical company that develops and commercializes treatments for underserved patient populations. The company's product portfolio consists of eleven commercial rare disease products spanning pediatric endocrinology (Alkindi Sprinkle, Khindivi, Increlex), metabolic disorders (Carglumic Acid, Betaine Anhydrous, Nitisinone), rare genetic conditions (Galzin for Wilson disease, PKU GoLike, TYR GoLike), and specialized therapeutics (Hemangeol for infantile hemangioma, Desmoda for diabetes insipidus, IMPAVIDO for leishmaniasis). Eton also maintains a pipeline of development candidates including ET-700 for Wilson disease and ET-801 for adrenal insufficiency. The company operates through a business model focused on acquiring, licensing, and rapidly commercializing approved therapies with existing safety and efficacy data, distributing products primarily through specialty pharmacy partners like Anovo.
Differentiator
Problem solved
Functional benefit
Brands
- Eton Cares: Patient support program offering $0 co-pay for eligible commercially insured patients and expanded assistance programs
- Alkindi Sprinkle
- Desmoda
- Hemangeol
- Increlex
- Galzin
- Khindivi
- PKU GoLike
- Carglumic Acid
- Betaine Anhydrous
- Nitisinone
Products and services
- Alkindi Sprinkle
Quantifiable outcome
- DESMODA projected peak annual sales of $30-50 million
- +3 more outcomes
Companies that use Eton Pharmaceuticals
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Eton Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Eton Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Knight TherapeuticscoreEton acquired exclusive U.S. commercialization rights to IMPAVIDO (miltefosine), the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis, from Knight Therapeutics. Rights take effect September 26, 2026. This expands Eton's rare disease portfolio and adds another 2026 product launch.
- Anovo Specialty PharmacycoreAnovo Specialty Pharmacy serves as the exclusive distribution partner for HEMANGEOL and other Eton products. The partnership includes integration with Eton Cares patient support program offering $0 co-pay for eligible commercially insured patients.
- Pierre Fabre Medicament SascoreEton in-licensed U.S. commercialization rights to HEMANGEOL (propranolol hydrochloride) Oral Solution from Pierre Fabre. HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma requiring systemic therapy. Eton took over U.S. commercialization on May 1, 2026. Transaction expected to be accretive to 2026 earnings.
- CROSSJECTminorIn March 2025, CROSSJECT partnered with Eton Pharmaceuticals to develop and commercialize ET-801, a ready-to-use hydrocortisone formulation for treating adrenal insufficiency crises. The partnership leverages Eton's U.S. hospital market expertise for this adrenal insufficiency treatment.
- IpsencoreEton Pharmaceuticals announced agreement to acquire Increlex (mecasermin) from Ipsen, expected to complete near the end of 2024. The acquisition strengthens Eton's portfolio for treating ultra-rare pediatric conditions, with immediate US commercialization and a transition period for global supply. Increlex is approved in 40 territories and treats severe IGF-1 deficiency.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Eton Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Ultragenyx Pharmaceutical: Commercial-stage rare disease biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. Comparable in targeting small patient populations with specialty-distributed therapeutics.
- ANI Pharmaceuticals: U.S. specialty pharmaceutical company that acquires, develops, and commercializes branded and generic prescription pharmaceuticals, including rare disease products. Similar in-licensing and acquisition-driven growth model.
- Amneal Pharmaceuticals: Specialty and generics pharmaceutical company with rare disease and specialty distribution capabilities. Comparable in building a portfolio through acquisitions and licensing of niche, difficult-to-formulate products.
- PTC Therapeutics: Commercial-stage biopharmaceutical company focused on rare disorders, particularly those with CNS and metabolic components. Comparable in targeting small rare disease populations with specialty-distributed therapies.
- Scilex Holding (Scilex Pharmaceuticals): Specialty pharmaceutical company focused on non-opioid pain and rare/specialty products, with similar small-cap commercialization profile and reliance on specialty distribution channels.
Broad incumbents
- BioMarin Pharmaceutical: Established rare disease-focused biopharmaceutical company with multiple commercial products for ultra-rare conditions. Larger and more diversified than Eton but operates the same orphan-disease commercialization model.
- Jazz Pharmaceuticals: Specialty pharmaceutical company with significant rare disease and neurology exposure. Comparable in distributing specialty medicines for limited patient populations, though at a much larger scale.
- Recordati Rare Diseases: European-headquartered specialty and rare disease pharmaceutical group with a dedicated rare disease business unit. Comparable model of acquiring and commercializing treatments for rare conditions globally.
- Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company historically focused on rare diseases, branded specialty products, and hospital therapeutics. Comparable in commercializing niche, often small-population therapies.
Regional players
- Hikma Pharmaceuticals: Specialty pharmaceutical company with branded and rare disease product lines across the Middle East, Europe, and the U.S. Comparable in product-acquisition-led specialty pharma growth, though with broader geographic footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Eton Pharmaceuticals social profiles
Digital presenceEton Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eton Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles10 records
Eton Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eton Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eton Pharmaceuticals
What does Eton Pharmaceuticals do?
Eton Pharmaceuticals acquires, develops, and commercializes FDA-approved rare disease treatments, including proprietary formulations of approved molecules for pediatric endocrinology, metabolic disorders, and other rare conditions. The company focuses on products with existing safety and efficacy data, targeting rapid commercialization through specialty pharmacy networks. Its commercial portfolio spans ten-plus products including Alkindi Sprinkle, DESMODA, Galzin, Hemangeol, Increlex, Khindivi, Betaine Anhydrous, Carglumic Acid, Nitisinone, PKU GoLike, TYR GoLike, and IMPAVIDO.
Is Eton Pharmaceuticals a public or private company?
Eton Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Eton Pharmaceuticals founded?
Eton Pharmaceuticals was founded in 2017. It employs 51 to 100 people.
Where is Eton Pharmaceuticals based?
Eton Pharmaceuticals is headquartered in Studio City, United States, in the North America region.
How does Eton Pharmaceuticals make money?
Two revenue lines are on record. Product Sales are the primary driver. The others are royalty Revenue.
Who are Eton Pharmaceuticals's main competitors?
Direct peers on record are Ultragenyx Pharmaceutical, ANI Pharmaceuticals, Amneal Pharmaceuticals, PTC Therapeutics and Scilex Holding (Scilex Pharmaceuticals). Broad incumbents are BioMarin Pharmaceutical, Jazz Pharmaceuticals, Recordati Rare Diseases and Mallinckrodt Pharmaceuticals. Hikma Pharmaceuticals is listed as a regional player.
Does Eton Pharmaceuticals have an API?
No public API is recorded for Eton Pharmaceuticals.
What industry is Eton Pharmaceuticals in?
Eton Pharmaceuticals's product category is Rare Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.